Severe autoimmune hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency as a complication of nivolumab treatment: A case report
{{output}}
In recent years, immune checkpoint inhibitors, such as programmed death-1 (PD-1) inhibitors, have become key therapeutic options for specific cancers, used as first-, second-, or third-line treatments for various metastatic conditions. Nivolumab, a programmed ... ...
